Our Review Summary
Framing – and placement of components within a story – can make such a difference. There was good balance and independent perspective in this story – such as this quote: “The (test’s) performance may decrease considerably when the test is used in a large population of healthy individuals.” But it came late, long after the story had led with the cheerleading sentence above.
Why This Matters
The story says that “probably only 40% adhere to the (colon cancer) screening schedule over time” That was one researcher’s estimate – someone with a vested financial interest in this research (as Philadelphia Inquirer reported, some of his technology was licensed by the company for this test). But the fact is that the CDC BRFSS survey estimates that about 60% of US adults are up to date with screening, most with colonoscopy. That is a big difference from 40%, and one has to wonder why that was not double-checked. Still, there clearly are a lot of people being missed. How to improve those numbers is up for debate. Stories about new types of screening need to make clear comparisons between the success rates of colonoscopies now and the possible success rates of these emerging technologies.
Criteria
Not Satisfactory
No mention of possible or projected costs. Other stories estimated in the $300 per test ballpark.
Not Satisfactory
The story gave the same basic benefits data that the other stories gave, but it, too, didn’t compare this data with any of the existing colon cancer screening methods, leaving readers with no good sense of the potential scope of the benefits suggested. There was only one vague reference to the new approach being able to find tumors on both sides of the colon, “a feat that is not always accomplished by colonoscopy.”
Not Satisfactory
No discussion of potential harms.
Satisfactory
The story included WebMD’s boilerplate language for such stories: “This study was presented at a medical conference. The findings should be considered preliminary as they have not yet undergone the “peer review” process, in which outside experts scrutinize the data prior to publication in a medical journal.”
Better yet, though, was the quote provided by Dr. Durado Brooks of the American Cancer Society: “The (test’s) performance may decrease considerably when the test is used in a large population of healthy individuals.” That’s the value of getting independent perspectives to evaluate evidence.
However, a significant limitation that is only indirectly noted is that initial accuracy studies in non-representative samples of cases and non-cases (like this study) usually overestimate performance. That is why they are planning another study.
Satisfactory
No disease mongering in this story
Satisfactory
Mixed bag: The story did include comments from two independent experts, which was good.
But the story never fully explained the lead researcher’s true ties to the company making the test. There was only this vague and unhelpful line: “Ahlquist and Mayo Clinic are working in collaboration with Exact Sciences Corp. of Madison, Wis., to develop the test.”
Nonethless, we’ll give the story the benefit of the doubt on this criterion.
Not Satisfactory
No meaningful comparison with existing colon cancer screening tests and no acknowledgement that there are other new tests now in development.
Satisfactory
The story explains that a clinical trial may begin in 2011 and said that the lead researcher believed that “if all goes well the test could be available soon after that.”
Not Satisfactory
Some attempt was made to explain what might be novel about this approach, but the story never mentioned that there are competing tests now in development. The New York Times was much better on this point, mentioning the competition in its very first words.
Satisfactory
The story appears to be based on things said at a news conference, not things said in a news release.
Total Score: 5 of 10 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like